Seeking Alpha

UBS cuts estimates on Alexion Pharmaceuticals (ALXN +3.1%), and lowers its price target to $53...

UBS cuts estimates on Alexion Pharmaceuticals (ALXN +3.1%), and lowers its price target to $53 from $55, keeping a Neutral rating on the firm. Shares are outgaining all issues listed on the NASDAQ-100.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector